Johnson & Johnson (NYSE:JNJ) says it is abandoning plans to buy Takeda Pharmaceutical’s (NYSE:TAK) TachoSil surgical patch product due to regulatory issues.
Takeda had announced the sale of TachoSil to J&J subsidiary Ethicon for $400M last May.
Federal Trade Commission Chairman Joseph Simons
earlier cited potential regulatory issues over the deal because J&J
also sells Evarrest, the only other U.S.-approved fibrin sealant patch
designed to stop bleeding during surgery.
https://seekingalpha.com/news/3559944-j-and-j-drops-deal-for-takedas-tachosil-surgical-patch
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.